TriClip G5 Delivery System (TCDS0801-NT, TCDS0801-NTW, TCDS0801-XT, TCDS0801-XTW)
ABBOTT MEDICAL · Decision date Feb 25, 2026
What did the FDA approve?
FDA records P230007/S019 as a supplement to PMA P230007, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 25, 2026.
FDA approval order statement
Approval for minor design changes to the clip locking mechanism in the implant and to the delivery system handle of the MitraClip G5 and TriClip G5 Delivery Systems.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 25, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P230007/S019
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NPS
- Decision code
- APPR
- Decision date
- Feb 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Tricuspid valve repair device, percutaneously delivered.
- Applicant
- Abbott Medical
- Product code
- NPS
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230007/S016 · Related supplement
TriClip Delivery System
P230007/S015 · Related supplement
TriClip G5 Delivery System
P230007/S017 · Related supplement
TriClip G4 Delivery System; TriClip G5 Delivery System
P230007/S018 · Related supplement
TriClip G4 System
P230007/S019 received
Application receipt date recorded by FDA.
P230007/S019 · FDA decision
Real-Time Process
P230007/S020 · Related supplement
TriClip G4 System
P230007/S021 · Related supplement
TriClip Systems
P230007/S022 · Related supplement
TriClip Delivery System
P230007/S023 · Related supplement
TriClip Systems
Timeline entries are records held by MedtechLedger for P230007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TriClip Delivery SystemP230007/S016 | ABBOTT MEDICAL | PMA supplement | Aug 18, 2025 | FDA |
TriClip G5 Delivery SystemP230007/S015 | ABBOTT MEDICAL | PMA supplement | Aug 20, 2025 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 30, 2025 | FDA | |
TriClip G4 SystemP230007/S018 | ABBOTT MEDICAL | PMA supplement | Oct 17, 2025 | FDA |
TriClip G4 SystemP230007/S020 | ABBOTT MEDICAL | PMA supplement | Mar 6, 2026 | FDA |
TriClip SystemsP230007/S021 | ABBOTT MEDICAL | PMA supplement | May 14, 2026 | FDA |
TriClip Delivery SystemP230007/S022 | ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA |
TriClip SystemsP230007/S023 | ABBOTT MEDICAL | PMA supplement | Jun 25, 2026 | FDA |
Explore the linked device profile
Other records with product code NPS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA supplement | Oct 20, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P230007/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





